•
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter of 2024, with revenues reaching USD 8.5 billion, an increase of 23% year-on-year (YOY). Product sales saw a 24% increase, with an 8% growth when excluding sales from the Horizon Therapeutics (Horizon) acquisition. In the…
•
Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with Sino Biopharmaceutical Ltd (HKG: 1177), along with controlling shareholder HOB Biotech Group Limited and John Li, chairman and general manager of HOB. The collaboration aims to explore and cooperate in the research and development, production,…
•
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024, reporting sales of USD 2.6 billion, reflecting a 12% year-on-year (YOY) increase in constant currency terms. Chemical generics contributed USD 1.854 billion in sales, marking a 4% YOY increase, while biosimilars saw a significant surge…
•
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter of 2024, reporting revenues of RMB 1.271 billion (USD 178.36 million) for the first three quarters, marking a 28.87% year-on-year (YOY) increase, and a net loss of RMB 927 million (USD 130 million). The third…
•
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) to terminate their strategic partnership, which was initially formed in December 2020 to support the launch of the hypoglycemic drug chiglitazar (Bilessglu) for type 2 diabetes in 19 provinces, including Henan,…
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for the third quarter of 2024, with total revenues increasing by 20% year-on-year (YOY) to USD 11.439 billion. The growth was propelled by volume increases from Mounjaro and Zepbound, as well as higher realized prices. In…
•
Leon Wang, Executive Vice President International and AstraZeneca (AZ, NASDAQ: AZN) China President, is cooperating with an investigation by Chinese authorities, as stated by the UK pharmaceutical major. During this period, AstraZeneca China General Manager Lai Minglong will ensure business continuity. This development follows a series of media reports about…
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the…
•
Jiangsu Yuyue Medical Equipment Inc., (SHE: 002223), a Chinese medical equipment manufacturer, has entered into a strategic partnership with Germany’s TÜV SUD, one of the world’s largest technical inspection institutions. The collaboration aims to enhance their cooperation in the medical device market access and quality system. With over two decades…
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2024, showing a modest 2% year-on-year (YOY) increase in revenue to GBP 8 billion (USD 10.496 billion) at constant exchange rates. The quarter’s performance was propelled by a 19% surge in the Specialty…
•
China-based Allmed Medical Products Co., Ltd (SHE: 002950) has announced plans to establish a wholly owned subsidiary in Indonesia with a registered capital of USD 50 million. The new entity, provisionally named PT Ace Medical Products Indonesia, will concentrate on the research and development, manufacturing, and sales of medical products…
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that the National Medical Products Administration (NMPA) in China has accepted for review another indication approval filing for its sacituzumab tirumotecan (SKB264/MK-2870). The new indication is for the treatment of locally advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC)…
•
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first patient in a randomized, controlled, multicenter Phase III clinical study (AK117-302), assessing the combination of the innovative PD-1/VEGF bispecific antibody ivonescimab and its next-generation CD47 monoclonal antibody ligufalimab (AK117) against pembrolizumab for the first-line treatment of PD-L1 positive…
•
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter ended September 30, 2024, with net revenues of USD 14.46 billion, marking a 4.9% increase year-on-year at constant exchange rates. The US market contributed USD 11.148 billion in sales, while the International Market (excluding the…
•
Shanghai Henlius Biotech Inc. (HKG: 2696) and its US partner Organon (NYSE: OGN) have jointly announced that the Biologic License Application (BLA) for HLX14, an investigational biosimilar of Amgen’s (NASDAQ: AMGN) Prolia/Xgeva (denosumab), has been accepted for review by the US Food and Drug Administration (FDA). Denosumab, a recombinant anti-RANKL…
•
Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion for the third quarter, a 32% year-on-year (YOY) increase at constant exchange rates. For the first nine months of the year, revenues totaled $45.864 billion, reflecting a 3% YOY growth. This strong performance has prompted…
•
AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its mRNA vaccine targeting respiratory syncytial virus (RSV). RSV is a leading cause of mortality in infants under one year old and significantly contributes to respiratory infections and…
•
Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received marketing approval from the National Medical Products Administration (NMPA) for its Acotrace, a disposable catheter sheath group. The Acotrace is designed for the insertion of medical devices, including guide wires and catheters, into blood vessels, facilitating percutaneous puncture access…
•
Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which its wholly owned subsidiary Fortvita will sell a 20% stake to Lostrancos Ventures Ltd. for USD 20.5 million. This news has sparked market controversy, with some investors criticizing the valuation of Fortvita as being too…
•
Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up results from the Phase III PIONEER study for its first-in-class HT Supreme drug-eluting stent system across the United States, Japan, and Europe. The HT Supreme system represents a significant milestone as the first cardiac stent…